-
Je něco špatně v tomto záznamu ?
Dual Infection of an Open Fracture Caused by Mycobacterium setense and Clostridium celerecrescens
L. Ryskova, J. Zahradnicek, R. Kukla, R. Bolehovska, M. Vajda, I. Pavlik, P. Bostik, P. Ryska
Jazyk angličtina Země Švýcarsko
Typ dokumentu kazuistiky
Grantová podpora
NU20-09-00114
Czech Health Research Council
NLK
Directory of Open Access Journals
od 2012
PubMed Central
od 2012
Europe PubMed Central
od 2012
ProQuest Central
od 2012-01-01
Open Access Digital Library
od 2012-01-01
Open Access Digital Library
od 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2012
- Publikační typ
- kazuistiky MeSH
Infections caused by Mycobacterium setense or Clostridium celerecrescens are extremely rare. In this report, for the first time a dual infection with these two pathogens is described. An 18-year-old female suffered multiple injuries, including an open comminuted fracture of the right humeral diaphysis after falling from a fifth-floor balcony in January 2019. Five months after the accident, a fistula appeared in the scar, reaching the bone tissue. M. setense and C. celerecrescens were cultured from sinus swabs and subsequently from perioperative samples. The patient was initially treated with a combination of intravenous antibiotics (ATBs): imipenem, amikacin, and ciprofloxacin. One month after the fracture fixation with a titanium nail, C. celerecrescens was again detected; therefore, metronidazole was added to the therapy. A triple combination of oral (PO) ATBs (trimethoprim-sulfamethoxazole, moxifloxacin, and metronidazole) followed, 8 weeks after the initial intravenous therapy. C. celerecrescens was cultured again two times, most recently in November 2019, when surgical debridement was supplemented by the topical administration of cancellous bone impregnated with vancomycin. Signs of bone healing were found at follow-ups and ATB treatment was finished in March 2020 after a total of 9 months of therapy. To this day, there have been no signs of reinfection. This case thus illustrates the need for a combination of systemic and individualized local therapy in the treatment of complicated cases of dual infections with rare pathogens.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22023302
- 003
- CZ-PrNML
- 005
- 20221031095139.0
- 007
- ta
- 008
- 221010s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/antibiotics11091254 $2 doi
- 035 __
- $a (PubMed)36140033
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Ryskova, Lenka $u Institute of Clinical Microbiology, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital, 50005 Hradec Kralove, Czech Republic
- 245 10
- $a Dual Infection of an Open Fracture Caused by Mycobacterium setense and Clostridium celerecrescens / $c L. Ryskova, J. Zahradnicek, R. Kukla, R. Bolehovska, M. Vajda, I. Pavlik, P. Bostik, P. Ryska
- 520 9_
- $a Infections caused by Mycobacterium setense or Clostridium celerecrescens are extremely rare. In this report, for the first time a dual infection with these two pathogens is described. An 18-year-old female suffered multiple injuries, including an open comminuted fracture of the right humeral diaphysis after falling from a fifth-floor balcony in January 2019. Five months after the accident, a fistula appeared in the scar, reaching the bone tissue. M. setense and C. celerecrescens were cultured from sinus swabs and subsequently from perioperative samples. The patient was initially treated with a combination of intravenous antibiotics (ATBs): imipenem, amikacin, and ciprofloxacin. One month after the fracture fixation with a titanium nail, C. celerecrescens was again detected; therefore, metronidazole was added to the therapy. A triple combination of oral (PO) ATBs (trimethoprim-sulfamethoxazole, moxifloxacin, and metronidazole) followed, 8 weeks after the initial intravenous therapy. C. celerecrescens was cultured again two times, most recently in November 2019, when surgical debridement was supplemented by the topical administration of cancellous bone impregnated with vancomycin. Signs of bone healing were found at follow-ups and ATB treatment was finished in March 2020 after a total of 9 months of therapy. To this day, there have been no signs of reinfection. This case thus illustrates the need for a combination of systemic and individualized local therapy in the treatment of complicated cases of dual infections with rare pathogens.
- 655 _2
- $a kazuistiky $7 D002363
- 700 1_
- $a Zahradnicek, Jan $u Department of Surgery, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital, 50005 Hradec Kralove, Czech Republic
- 700 1_
- $a Kukla, Rudolf $u Institute of Clinical Microbiology, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital, 50005 Hradec Kralove, Czech Republic
- 700 1_
- $a Bolehovska, Radka $u Institute of Clinical Microbiology, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital, 50005 Hradec Kralove, Czech Republic
- 700 1_
- $a Vajda, Milan $u Department of Diagnostic Radiology, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital, 50005 Hradec Kralove, Czech Republic $1 0000000200648814
- 700 1_
- $a Pavlik, Ivo $u Faculty of Regional Development and International Studies, Mendel University in Brno, tr. Generala Piky 7, 61300 Brno, Czech Republic $1 0000000257713381
- 700 1_
- $a Bostik, Pavel $u Institute of Clinical Microbiology, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital, 50005 Hradec Kralove, Czech Republic $1 0000000326916458
- 700 1_
- $a Ryska, Pavel $u Department of Diagnostic Radiology, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital, 50005 Hradec Kralove, Czech Republic $1 0000000277930375
- 773 0_
- $w MED00195446 $t Antibiotics (Basel, Switzerland) $x 2079-6382 $g Roč. 11, č. 9 (2022)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36140033 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20221010 $b ABA008
- 991 __
- $a 20221031095136 $b ABA008
- 999 __
- $a ind $b bmc $g 1853803 $s 1174590
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 11 $c 9 $e 20220915 $i 2079-6382 $m Antibiotics (Basel) $n Antibiotics $x MED00195446
- GRA __
- $a NU20-09-00114 $p Czech Health Research Council
- LZP __
- $a Pubmed-20221010